Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
 Back to Details

Connection

Peter Gottlieb to Diabetes Mellitus, Type 1

This is a "connection" page, showing publications Peter Gottlieb has written about Diabetes Mellitus, Type 1.

 
Connection Strength
  
 
 
6.678
  
  1. Smith MJ, Cambier JC, Gottlieb PA. Endotypes in T1D: B lymphocytes and early onset. Curr Opin Endocrinol Diabetes Obes. 2020 08; 27(4):225-230.
    View in: PubMed
    Score: 0.213
  2. Michels AW, Gottlieb PA. Learning From Past Failures of Oral Insulin Trials. Diabetes. 2018 07; 67(7):1211-1215.
    View in: PubMed
    Score: 0.184
  3. Gottlieb PA. What defines disease in an age of genetics and biomarkers? Curr Opin Endocrinol Diabetes Obes. 2015 Aug; 22(4):296-9.
    View in: PubMed
    Score: 0.150
  4. Gottlieb PA, Alkanani AK, Michels AW, Lewis EC, Shapiro L, Dinarello CA, Zipris D. a1-Antitrypsin therapy downregulates toll-like receptor-induced IL-1? responses in monocytes and myeloid dendritic cells and may improve islet function in recently diagnosed patients with type 1 diabetes. J Clin Endocrinol Metab. 2014 Aug; 99(8):E1418-26.
    View in: PubMed
    Score: 0.136
  5. Gottlieb PA, Delong T, Baker RL, Fitzgerald-Miller L, Wagner R, Cook G, Rewers MR, Michels A, Haskins K. Chromogranin A is a T cell antigen in human type 1 diabetes. J Autoimmun. 2014 May; 50:38-41.
    View in: PubMed
    Score: 0.134
  6. Gottlieb P, Utz PJ, Robinson W, Steinman L. Clinical optimization of antigen specific modulation of type 1 diabetes with the plasmid DNA platform. Clin Immunol. 2013 Dec; 149(3):297-306.
    View in: PubMed
    Score: 0.132
  7. Gottlieb PA, Yu L, Babu S, Wenzlau J, Bellin M, Frohnert BI, Moran A. No relation between cystic fibrosis-related diabetes and type 1 diabetes autoimmunity. Diabetes Care. 2012 Aug; 35(8):e57.
    View in: PubMed
    Score: 0.122
  8. Garg SK, Voelmle M, Gottlieb PA. Time lag characterization of two continuous glucose monitoring systems. Diabetes Res Clin Pract. 2010 Mar; 87(3):348-53.
    View in: PubMed
    Score: 0.103
  9. Gottlieb PA, Quinlan S, Krause-Steinrauf H, Greenbaum CJ, Wilson DM, Rodriguez H, Schatz DA, Moran AM, Lachin JM, Skyler JS. Failure to preserve beta-cell function with mycophenolate mofetil and daclizumab combined therapy in patients with new- onset type 1 diabetes. Diabetes Care. 2010 Apr; 33(4):826-32.
    View in: PubMed
    Score: 0.102
  10. Rewers M, Gottlieb P. Immunotherapy for the prevention and treatment of type 1 diabetes: human trials and a look into the future. Diabetes Care. 2009 Oct; 32(10):1769-82.
    View in: PubMed
    Score: 0.100
  11. Aly H, Gottlieb P. The honeymoon phase: intersection of metabolism and immunology. Curr Opin Endocrinol Diabetes Obes. 2009 Aug; 16(4):286-92.
    View in: PubMed
    Score: 0.099
  12. Garg SK, Smith J, Beatson C, Lopez-Baca B, Voelmle M, Gottlieb PA. Comparison of accuracy and safety of the SEVEN and the Navigator continuous glucose monitoring systems. Diabetes Technol Ther. 2009 Feb; 11(2):65-72.
    View in: PubMed
    Score: 0.096
  13. Garg SK, Voelmle MK, Gottlieb P. Feasibility of 10-day use of a continuous glucose-monitoring system in adults with type 1 diabetes. Diabetes Care. 2009 Mar; 32(3):436-8.
    View in: PubMed
    Score: 0.095
  14. Garg SK, Bookout TR, McFann KK, Kelly WC, Beatson C, Ellis SL, Gutin RS, Gottlieb PA. Improved glycemic control in intensively treated adult subjects with type 1 diabetes using insulin guidance software. Diabetes Technol Ther. 2008 Oct; 10(5):369-75.
    View in: PubMed
    Score: 0.094
  15. Alleva DG, Maki RA, Putnam AL, Robinson JM, Kipnes MS, Dandona P, Marks JB, Simmons DL, Greenbaum CJ, Jimenez RG, Conlon PJ, Gottlieb PA. Immunomodulation in type 1 diabetes by NBI-6024, an altered peptide ligand of the insulin B epitope. Scand J Immunol. 2006 Jan; 63(1):59-69.
    View in: PubMed
    Score: 0.077
  16. Hohenstein AC, Gallegos JB, Dang M, Groegler J, Broncucia H, Tensun FA, Waugh K, Dong F, James EA, Speake C, Steck AK, Rewers MJ, Gottlieb PA, Haskins K, Delong T, Baker RL. Novel T-Cell Reactivities to Hybrid Insulin Peptides in Islet Autoantibody-Positive At-Risk Individuals. Diabetes. 2025 Jun 01; 74(6):933-942.
    View in: PubMed
    Score: 0.074
  17. Gottlieb PA. In vitro and in vivo approaches to prevention and cure of T1D. Curr Diab Rep. 2005 Apr; 5(2):77-8.
    View in: PubMed
    Score: 0.073
  18. Nicholas CA, Tensun FA, Evans SA, Toole KP, Prendergast JE, Broncucia H, Hesselberth JR, Gottlieb PA, Wells KL, Smith MJ. Activated polyreactive B cells are clonally expanded in autoantibody positive and patients with recent-onset type 1 diabetes. Cell Rep. 2025 Apr 22; 44(4):115425.
    View in: PubMed
    Score: 0.073
  19. Triolo TM, Parikh HM, Tosur M, Ferrat LA, You L, Gottlieb PA, Oram RA, Onengut-Gumuscu S, Krischer JP, Rich SS, Steck AK, Redondo MJ. Genetic Associations With C-peptide Levels Before Type 1 Diabetes Diagnosis in At-risk Relatives. J Clin Endocrinol Metab. 2025 Mar 17; 110(4):e1046-e1050.
    View in: PubMed
    Score: 0.073
  20. Putnam AL, Vendrame F, Dotta F, Gottlieb PA. CD4+CD25high regulatory T cells in human autoimmune diabetes. J Autoimmun. 2005 Feb; 24(1):55-62.
    View in: PubMed
    Score: 0.072
  21. Sooy M, Pyle L, Alonso GT, Broncucia HC, Rewers A, Gottlieb PA, Simmons KM, Rewers MJ, Steck AK. Lower Prevalence of Diabetic Ketoacidosis at Diagnosis in Research Participants Monitored for Hyperglycemia. J Clin Endocrinol Metab. 2024 Dec 18; 110(1):e80-e86.
    View in: PubMed
    Score: 0.072
  22. Barker JM, Ide A, Hostetler C, Yu L, Miao D, Fain PR, Eisenbarth GS, Gottlieb PA. Endocrine and immunogenetic testing in individuals with type 1 diabetes and 21-hydroxylase autoantibodies: Addison's disease in a high-risk population. J Clin Endocrinol Metab. 2005 Jan; 90(1):128-34.
    View in: PubMed
    Score: 0.071
  23. Triolo TM, Jacobsen LM, Cuthbertson D, Sims EK, Ismail HM, Redondo MJ, Lundgren M, DiMeglio LA, Gottlieb PA, Atkinson MA, Krischer JP, Schatz DA, Sosenko JM. Effect of Oral Insulin on Early Combined Glucose and C-Peptide Endpoints in Individuals at High-Risk for Type 1 Diabetes. Pediatr Diabetes. 2024; 2024:8343868.
    View in: PubMed
    Score: 0.071
  24. Garg SK, Paul JM, Karsten JI, Menditto L, Gottlieb PA. Reduced severe hypoglycemia with insulin glargine in intensively treated adults with type 1 diabetes. Diabetes Technol Ther. 2004 Oct; 6(5):589-95.
    View in: PubMed
    Score: 0.071
  25. Jacobsen LM, Cuthbertson D, Bundy BN, Atkinson MA, Moore W, Haller MJ, Russell WE, Gitelman SE, Herold KC, Redondo MJ, Sims EK, Wherrett DK, Moran A, Pugliese A, Gottlieb PA, Sosenko JM, Ismail HM. Early Metabolic Endpoints Identify Persistent Treatment Efficacy in Recent-Onset Type 1 Diabetes Immunotherapy Trials. Diabetes Care. 2024 Jun 01; 47(6):1048-1055.
    View in: PubMed
    Score: 0.069
  26. Callebaut A, Guyer P, Baker RL, Gallegos JB, Hohenstein AC, Gottlieb PA, Mathieu C, Overbergh L, Haskins K, James EA. An Insulin-Chromogranin A Hybrid Peptide Activates DR11-Restricted T Cells in Human Type 1 Diabetes. Diabetes. 2024 May 01; 73(5):743-750.
    View in: PubMed
    Score: 0.069
  27. Vendrame F, Gottlieb PA. Prediabetes: prediction and prevention trials. Endocrinol Metab Clin North Am. 2004 Mar; 33(1):75-92, ix.
    View in: PubMed
    Score: 0.068
  28. Gottlieb PA. Type 1 diabetes. Endocrinol Metab Clin North Am. 2004 Mar; 33(1):xiii-xiv.
    View in: PubMed
    Score: 0.068
  29. Taylor PN, Collins KS, Lam A, Karpen SR, Greeno B, Walker F, Lozano A, Atabakhsh E, Ahmed ST, Marinac M, Latres E, Senior PA, Rigby M, Gottlieb PA, Dayan CM. C-peptide and metabolic outcomes in trials of disease modifying therapy in new-onset type 1 diabetes: an individual participant meta-analysis. Lancet Diabetes Endocrinol. 2023 12; 11(12):915-925.
    View in: PubMed
    Score: 0.067
  30. Herold KC, Gitelman SE, Gottlieb PA, Knecht LA, Raymond R, Ramos EL. Teplizumab: A Disease-Modifying Therapy for Type 1 Diabetes That Preserves ?-Cell Function. Diabetes Care. 2023 10 01; 46(10):1848-1856.
    View in: PubMed
    Score: 0.066
  31. Sharma S, Tan X, Boyer J, Clarke D, Costanzo A, Abe B, Kain L, Holt M, Armstrong A, Rihanek M, Su A, Speake C, Gottlieb P, Gottschalk M, Pettus J, Teyton L. Measuring anti-islet autoimmunity in mouse and human by profiling peripheral blood antigen-specific CD4 T cells. Sci Transl Med. 2023 07 05; 15(703):eade3614.
    View in: PubMed
    Score: 0.065
  32. Stensland ZC, Magera CA, Broncucia H, Gomez BD, Rios-Guzman NM, Wells KL, Nicholas CA, Rihanek M, Hunter MJ, Toole KP, Gottlieb PA, Smith MJ. Identification of an anergic BND cell-derived activated B cell population (BND2) in young-onset type 1 diabetes patients. J Exp Med. 2023 08 07; 220(8).
    View in: PubMed
    Score: 0.064
  33. Russell WE, Bundy BN, Anderson MS, Cooney LA, Gitelman SE, Goland RS, Gottlieb PA, Greenbaum CJ, Haller MJ, Krischer JP, Libman IM, Linsley PS, Long SA, Lord SM, Moore DJ, Moore WV, Moran AM, Muir AB, Raskin P, Skyler JS, Wentworth JM, Wherrett DK, Wilson DM, Ziegler AG, Herold KC. Abatacept for Delay of Type 1 Diabetes Progression in Stage 1 Relatives at Risk: A Randomized, Double-Masked, Controlled Trial. Diabetes Care. 2023 05 01; 46(5):1005-1013.
    View in: PubMed
    Score: 0.064
  34. Mitchell AM, Baschal EE, McDaniel KA, Simmons KM, Pyle L, Waugh K, Steck AK, Yu L, Gottlieb PA, Rewers MJ, Nakayama M, Michels AW. Temporal development of T cell receptor repertoires during childhood in health and disease. JCI Insight. 2022 09 22; 7(18).
    View in: PubMed
    Score: 0.062
  35. Gottlieb PA, Hayward AR. Cytokine and immunosuppressive therapies of type 1 diabetes mellitus. Endocrinol Metab Clin North Am. 2002 Jun; 31(2):477-95.
    View in: PubMed
    Score: 0.060
  36. Triolo TM, Pyle L, Broncucia H, Armstrong T, Yu L, Gottlieb PA, Steck AK. Association of High-Affinity Autoantibodies With Type 1 Diabetes High-Risk HLA Haplotypes. J Clin Endocrinol Metab. 2022 03 24; 107(4):e1510-e1517.
    View in: PubMed
    Score: 0.060
  37. Gottlieb PA, Eisenbarth GS. Insulin-specific tolerance in diabetes. Clin Immunol. 2002 Jan; 102(1):2-11.
    View in: PubMed
    Score: 0.059
  38. Gottlieb PA, Frias JP, Peters KA, Chillara B, Garg SK. Optimizing insulin therapy in pregnant women with type 1 diabetes mellitus. Treat Endocrinol. 2002; 1(4):235-40.
    View in: PubMed
    Score: 0.059
  39. Bediaga NG, Li-Wai-Suen CSN, Haller MJ, Gitelman SE, Evans-Molina C, Gottlieb PA, Hippich M, Ziegler AG, Lernmark A, DiMeglio LA, Wherrett DK, Colman PG, Harrison LC, Wentworth JM. Simplifying prediction of disease progression in pre-symptomatic type 1 diabetes using a single blood sample. Diabetologia. 2021 11; 64(11):2432-2444.
    View in: PubMed
    Score: 0.057
  40. Gitelman SE, Bundy BN, Ferrannini E, Lim N, Blanchfield JL, DiMeglio LA, Felner EI, Gaglia JL, Gottlieb PA, Long SA, Mari A, Mirmira RG, Raskin P, Sanda S, Tsalikian E, Wentworth JM, Willi SM, Krischer JP, Bluestone JA. Imatinib therapy for patients with recent-onset type 1 diabetes: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Diabetes Endocrinol. 2021 08; 9(8):502-514.
    View in: PubMed
    Score: 0.057
  41. Lin A, Mack JA, Bruggeman B, Jacobsen LM, Posgai AL, Wasserfall CH, Brusko TM, Atkinson MA, Gitelman SE, Gottlieb PA, Gurka MJ, Mathews CE, Schatz DA, Haller MJ. Low-Dose ATG/GCSF in Established Type 1 Diabetes: A Five-Year Follow-up Report. Diabetes. 2021 05; 70(5):1123-1129.
    View in: PubMed
    Score: 0.055
  42. Mitchell AM, Alkanani AA, McDaniel KA, Pyle L, Waugh K, Steck AK, Nakayama M, Yu L, Gottlieb PA, Rewers MJ, Michels AW. T-cell responses to hybrid insulin peptides prior to type 1 diabetes development. Proc Natl Acad Sci U S A. 2021 02 09; 118(6).
    View in: PubMed
    Score: 0.055
  43. Stephens E, Robinson JA, Gottlieb PA. Becaplermin and necrobiosis lipoidicum diabeticorum: results of a case control pilot study. J Diabetes Complications. 2001 Jan-Feb; 15(1):55-6.
    View in: PubMed
    Score: 0.055
  44. Herold KC, Reynolds J, Dziura J, Baidal D, Gaglia J, Gitelman SE, Gottlieb PA, Marks J, Philipson LH, Pop-Busui R, Weinstock RS. Exenatide extended release in patients with type 1 diabetes with and without residual insulin production. Diabetes Obes Metab. 2020 11; 22(11):2045-2054.
    View in: PubMed
    Score: 0.053
  45. Wentworth JM, Bediaga NG, Gitelman SE, Evans-Molina C, Gottlieb PA, Colman PG, Haller MJ, Harrison LC. Clinical trial data validate the C-peptide estimate model in type 1 diabetes. Diabetologia. 2020 04; 63(4):885-886.
    View in: PubMed
    Score: 0.051
  46. Herold KC, Bucktrout SL, Wang X, Bode BW, Gitelman SE, Gottlieb PA, Hughes J, Joh T, McGill JB, Pettus JH, Potluri S, Schatz D, Shannon M, Udata C, Wong G, Levisetti M, Ganguly BJ, Garzone PD. Immunomodulatory activity of humanized anti-IL-7R monoclonal antibody RN168 in subjects with type 1 diabetes. JCI Insight. 2019 12 19; 4(24).
    View in: PubMed
    Score: 0.051
  47. Battaglia M, Ahmed S, Anderson MS, Atkinson MA, Becker D, Bingley PJ, Bosi E, Brusko TM, DiMeglio LA, Evans-Molina C, Gitelman SE, Greenbaum CJ, Gottlieb PA, Herold KC, Hessner MJ, Knip M, Jacobsen L, Krischer JP, Long SA, Lundgren M, McKinney EF, Morgan NG, Oram RA, Pastinen T, Peters MC, Petrelli A, Qian X, Redondo MJ, Roep BO, Schatz D, Skibinski D, Peakman M. Introducing the Endotype Concept to Address the Challenge of Disease Heterogeneity in Type 1 Diabetes. Diabetes Care. 2020 01; 43(1):5-12.
    View in: PubMed
    Score: 0.051
  48. Sharma S, Pettus J, Gottschalk M, Abe B, Gottlieb P, Teyton L. Single-Cell Analysis of CD4 T Cells in Type 1 Diabetes: From Mouse to Man, How to Perform Mechanistic Studies. Diabetes. 2019 10; 68(10):1886-1891.
    View in: PubMed
    Score: 0.050
  49. Simmons KM, Fouts A, Pyle L, Clark P, Dong F, Yu L, Usmani-Brown S, Gottlieb P, Herold KC, Steck AK. Unmethylated Insulin as an Adjunctive Marker of Beta Cell Death and Progression to Type 1 Diabetes in Participants at Risk for Diabetes. Int J Mol Sci. 2019 08 08; 20(16).
    View in: PubMed
    Score: 0.050
  50. Herold KC, Bundy BN, Long SA, Bluestone JA, DiMeglio LA, Dufort MJ, Gitelman SE, Gottlieb PA, Krischer JP, Linsley PS, Marks JB, Moore W, Moran A, Rodriguez H, Russell WE, Schatz D, Skyler JS, Tsalikian E, Wherrett DK, Ziegler AG, Greenbaum CJ. An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes. N Engl J Med. 2019 08 15; 381(7):603-613.
    View in: PubMed
    Score: 0.049
  51. Baker RL, Rihanek M, Hohenstein AC, Nakayama M, Michels A, Gottlieb PA, Haskins K, Delong T. Hybrid Insulin Peptides Are Autoantigens in Type 1 Diabetes. Diabetes. 2019 09; 68(9):1830-1840.
    View in: PubMed
    Score: 0.049
  52. Haller MJ, Long SA, Blanchfield JL, Schatz DA, Skyler JS, Krischer JP, Bundy BN, Geyer SM, Warnock MV, Miller JL, Atkinson MA, Becker DJ, Baidal DA, DiMeglio LA, Gitelman SE, Goland R, Gottlieb PA, Herold KC, Marks JB, Moran A, Rodriguez H, Russell WE, Wilson DM, Greenbaum CJ. Low-Dose Anti-Thymocyte Globulin Preserves C-Peptide, Reduces HbA1c, and Increases Regulatory to Conventional T-Cell Ratios in New-Onset Type 1 Diabetes: Two-Year Clinical Trial Data. Diabetes. 2019 06; 68(6):1267-1276.
    View in: PubMed
    Score: 0.049
  53. Ostrov DA, Gottlieb PA, Michels AW. Rationally designed small molecules to prevent type 1 diabetes. Curr Opin Endocrinol Diabetes Obes. 2019 04; 26(2):90-95.
    View in: PubMed
    Score: 0.048
  54. Perdigoto AL, Preston-Hurlburt P, Clark P, Long SA, Linsley PS, Harris KM, Gitelman SE, Greenbaum CJ, Gottlieb PA, Hagopian W, Woodwyk A, Dziura J, Herold KC. Treatment of type 1 diabetes with teplizumab: clinical and immunological follow-up after 7?years from diagnosis. Diabetologia. 2019 04; 62(4):655-664.
    View in: PubMed
    Score: 0.048
  55. Gottlieb PA. Lazarus rises: islet regeneration in the 21st century. Diabetes Metab Rev. 1998 Dec; 14(4):330-1.
    View in: PubMed
    Score: 0.047
  56. Harms RZ, Lorenzo-Arteaga KM, Ostlund KR, Smith VB, Smith LM, Gottlieb P, Sarvetnick N. Abnormal T Cell Frequencies, Including Cytomegalovirus-Associated Expansions, Distinguish Seroconverted Subjects at Risk for Type 1 Diabetes. Front Immunol. 2018; 9:2332.
    View in: PubMed
    Score: 0.047
  57. Gavin PG, Mullaney JA, Loo D, Cao KL, Gottlieb PA, Hill MM, Zipris D, Hamilton-Williams EE. Intestinal Metaproteomics Reveals Host-Microbiota Interactions in Subjects at Risk for Type 1 Diabetes. Diabetes Care. 2018 10; 41(10):2178-2186.
    View in: PubMed
    Score: 0.046
  58. Triolo TM, Fouts A, Pyle L, Yu L, Gottlieb PA, Steck AK. Identical and Nonidentical Twins: Risk and Factors Involved in Development of Islet Autoimmunity and Type 1 Diabetes. Diabetes Care. 2019 02; 42(2):192-199.
    View in: PubMed
    Score: 0.046
  59. Haller MJ, Schatz DA, Skyler JS, Krischer JP, Bundy BN, Miller JL, Atkinson MA, Becker DJ, Baidal D, DiMeglio LA, Gitelman SE, Goland R, Gottlieb PA, Herold KC, Marks JB, Moran A, Rodriguez H, Russell W, Wilson DM, Greenbaum CJ. Low-Dose Anti-Thymocyte Globulin (ATG) Preserves ?-Cell Function and Improves HbA1c in New-Onset Type 1 Diabetes. Diabetes Care. 2018 Sep; 41(9):1917-1925.
    View in: PubMed
    Score: 0.046
  60. Greenbaum CJ, Speake C, Krischer J, Buckner J, Gottlieb PA, Schatz DA, Herold KC, Atkinson MA. Strength in Numbers: Opportunities for Enhancing the Development of Effective Treatments for Type 1 Diabetes-The TrialNet Experience. Diabetes. 2018 07; 67(7):1216-1225.
    View in: PubMed
    Score: 0.046
  61. Smith MJ, Rihanek M, Wasserfall C, Mathews CE, Atkinson MA, Gottlieb PA, Cambier JC. Loss of B-Cell Anergy in Type 1 Diabetes Is Associated With High-Risk HLA and Non-HLA Disease Susceptibility Alleles. Diabetes. 2018 04; 67(4):697-703.
    View in: PubMed
    Score: 0.045
  62. Gottlieb PA, Eisenbarth GS. Diagnosis and treatment of pre-insulin dependent diabetes. Annu Rev Med. 1998; 49:391-405.
    View in: PubMed
    Score: 0.044
  63. Battaglia M, Anderson MS, Buckner JH, Geyer SM, Gottlieb PA, Kay TWH, Lernmark ?, Muller S, Pugliese A, Roep BO, Greenbaum CJ, Peakman M. Understanding and preventing type 1 diabetes through the unique working model of TrialNet. Diabetologia. 2017 Nov; 60(11):2139-2147.
    View in: PubMed
    Score: 0.043
  64. Bosi E, Boulware DC, Becker DJ, Buckner JH, Geyer S, Gottlieb PA, Henderson C, Kinderman A, Sosenko JM, Steck AK, Bingley PJ. Impact of Age and Antibody Type on Progression From Single to Multiple Autoantibodies in Type 1 Diabetes Relatives. J Clin Endocrinol Metab. 2017 08 01; 102(8):2881-2886.
    View in: PubMed
    Score: 0.043
  65. Sosenko JM, Yu L, Skyler JS, Krischer JP, Gottlieb PA, Boulware D, Miao D, Palmer JP, Steck AK. The Use of Electrochemiluminescence Assays to Predict Autoantibody and Glycemic Progression Toward Type 1 Diabetes in Individuals with Single Autoantibodies. Diabetes Technol Ther. 2017 03; 19(3):183-187.
    View in: PubMed
    Score: 0.042
  66. Michels AW, Landry LG, McDaniel KA, Yu L, Campbell-Thompson M, Kwok WW, Jones KL, Gottlieb PA, Kappler JW, Tang Q, Roep BO, Atkinson MA, Mathews CE, Nakayama M. Islet-Derived CD4 T Cells Targeting Proinsulin in Human Autoimmune Diabetes. Diabetes. 2017 03; 66(3):722-734.
    View in: PubMed
    Score: 0.041
  67. Simmons KM, Gottlieb PA, Michels AW. Immune Intervention and Preservation of Pancreatic Beta Cell Function in Type 1 Diabetes. Curr Diab Rep. 2016 10; 16(10):97.
    View in: PubMed
    Score: 0.041
  68. Haller MJ, Gitelman SE, Gottlieb PA, Michels AW, Perry DJ, Schultz AR, Hulme MA, Shuster JJ, Zou B, Wasserfall CH, Posgai AL, Mathews CE, Brusko TM, Atkinson MA, Schatz DA. Antithymocyte Globulin Plus G-CSF Combination Therapy Leads to Sustained Immunomodulatory and Metabolic Effects in a Subset of Responders With Established Type 1 Diabetes. Diabetes. 2016 Dec; 65(12):3765-3775.
    View in: PubMed
    Score: 0.041
  69. Fouts A, Pyle L, Yu L, Miao D, Michels A, Krischer J, Sosenko J, Gottlieb P, Steck AK. Do Electrochemiluminescence Assays Improve Prediction of Time to Type 1 Diabetes in Autoantibody-Positive TrialNet Subjects? Diabetes Care. 2016 Oct; 39(10):1738-44.
    View in: PubMed
    Score: 0.040
  70. Gitelman SE, Gottlieb PA, Felner EI, Willi SM, Fisher LK, Moran A, Gottschalk M, Moore WV, Pinckney A, Keyes-Elstein L, Harris KM, Kanaparthi S, Phippard D, Ding L, Bluestone JA, Ehlers MR. Antithymocyte globulin therapy for patients with recent-onset type 1 diabetes: 2?year results of a randomised trial. Diabetologia. 2016 06; 59(6):1153-61.
    View in: PubMed
    Score: 0.039
  71. Gottlieb PA, Eisenbarth GS. Mouse and man: multiple genes and multiple autoantigens in the aetiology of type I DM and related autoimmune disorders. J Autoimmun. 1996 Apr; 9(2):277-81.
    View in: PubMed
    Score: 0.039
  72. Steck AK, Fouts A, Miao D, Zhao Z, Dong F, Sosenko J, Gottlieb P, Rewers MJ, Yu L. ECL-IAA and ECL-GADA Can Identify High-Risk Single Autoantibody-Positive Relatives in the TrialNet Pathway to Prevention Study. Diabetes Technol Ther. 2016 07; 18(7):410-4.
    View in: PubMed
    Score: 0.039
  73. Sunni M, Noble JA, Yu L, Mahamed Z, Lane JA, Dhunkal AM, Bellin MD, Nathan B, Kyllo J, Abuzzahab MJ, Gottlieb PA, Babu S, Armstrong T, Moran A. Predominance of DR3 in Somali children with type 1 diabetes in the twin cities, Minnesota. Pediatr Diabetes. 2017 03; 18(2):136-142.
    View in: PubMed
    Score: 0.039
  74. Insel RA, Dunne JL, Atkinson MA, Chiang JL, Dabelea D, Gottlieb PA, Greenbaum CJ, Herold KC, Krischer JP, Lernmark ?, Ratner RE, Rewers MJ, Schatz DA, Skyler JS, Sosenko JM, Ziegler AG. Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association. Diabetes Care. 2015 Oct; 38(10):1964-74.
    View in: PubMed
    Score: 0.038
  75. Wherrett DK, Chiang JL, Delamater AM, DiMeglio LA, Gitelman SE, Gottlieb PA, Herold KC, Lovell DJ, Orchard TJ, Ryan CM, Schatz DA, Wendler DS, Greenbaum CJ. Defining pathways for development of disease-modifying therapies in children with type 1 diabetes: a consensus report. Diabetes Care. 2015 Oct; 38(10):1975-85.
    View in: PubMed
    Score: 0.038
  76. Rigby MR, Harris KM, Pinckney A, DiMeglio LA, Rendell MS, Felner EI, Dostou JM, Gitelman SE, Griffin KJ, Tsalikian E, Gottlieb PA, Greenbaum CJ, Sherry NA, Moore WV, Monzavi R, Willi SM, Raskin P, Keyes-Elstein L, Long SA, Kanaparthi S, Lim N, Phippard D, Soppe CL, Fitzgibbon ML, McNamara J, Nepom GT, Ehlers MR. Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patients. J Clin Invest. 2015 Aug 03; 125(8):3285-96.
    View in: PubMed
    Score: 0.038
  77. Alkanani AK, Hara N, Gottlieb PA, Ir D, Robertson CE, Wagner BD, Frank DN, Zipris D. Alterations in Intestinal Microbiota Correlate With Susceptibility to Type 1 Diabetes. Diabetes. 2015 Oct; 64(10):3510-20.
    View in: PubMed
    Score: 0.037
  78. Nakayama M, McDaniel K, Fitzgerald-Miller L, Kiekhaefer C, Snell-Bergeon JK, Davidson HW, Rewers M, Yu L, Gottlieb P, Kappler JW, Michels A. Regulatory vs. inflammatory cytokine T-cell responses to mutated insulin peptides in healthy and type 1 diabetic subjects. Proc Natl Acad Sci U S A. 2015 Apr 07; 112(14):4429-34.
    View in: PubMed
    Score: 0.037
  79. Bellin MD, Moran A, Wilhelm JJ, O'Brien TD, Gottlieb PA, Yu L, Dunn TB. Development of Autoimmune-Mediated ? Cell Failure After Total Pancreatectomy With Autologous Islet Transplantation. Am J Transplant. 2015 Jul; 15(7):1991-4.
    View in: PubMed
    Score: 0.037
  80. Smith MJ, Packard TA, O'Neill SK, Henry Dunand CJ, Huang M, Fitzgerald-Miller L, Stowell D, Hinman RM, Wilson PC, Gottlieb PA, Cambier JC. Loss of anergic B cells in prediabetic and new-onset type 1 diabetic patients. Diabetes. 2015 May; 64(5):1703-12.
    View in: PubMed
    Score: 0.036
  81. Haller MJ, Gitelman SE, Gottlieb PA, Michels AW, Rosenthal SM, Shuster JJ, Zou B, Brusko TM, Hulme MA, Wasserfall CH, Mathews CE, Atkinson MA, Schatz DA. Anti-thymocyte globulin/G-CSF treatment preserves ? cell function in patients with established type 1 diabetes. J Clin Invest. 2015 Jan; 125(1):448-55.
    View in: PubMed
    Score: 0.036
  82. Aronson R, Gottlieb PA, Christiansen JS, Donner TW, Bosi E, Bode BW, Pozzilli P. Low-dose otelixizumab anti-CD3 monoclonal antibody DEFEND-1 study: results of the randomized phase III study in recent-onset human type 1 diabetes. Diabetes Care. 2014 Oct; 37(10):2746-54.
    View in: PubMed
    Score: 0.035
  83. Orban T, Beam CA, Xu P, Moore K, Jiang Q, Deng J, Muller S, Gottlieb P, Spain L, Peakman M. Reduction in CD4 central memory T-cell subset in costimulation modulator abatacept-treated patients with recent-onset type 1 diabetes is associated with slower C-peptide decline. Diabetes. 2014 Oct; 63(10):3449-57.
    View in: PubMed
    Score: 0.035
  84. Zhang L, Londono P, Yu L, Grimes S, Blackburn P, Gottlieb P, Eisenbarth GS. MAS-1 adjuvant immunotherapy generates robust Th2 type and regulatory immune responses providing long-term protection from diabetes in late-stage pre-diabetic NOD mice. Autoimmunity. 2014 Aug; 47(5):341-50.
    View in: PubMed
    Score: 0.034
  85. Orban T, Bundy B, Becker DJ, Dimeglio LA, Gitelman SE, Goland R, Gottlieb PA, Greenbaum CJ, Marks JB, Monzavi R, Moran A, Peakman M, Raskin P, Russell WE, Schatz D, Wherrett DK, Wilson DM, Krischer JP, Skyler JS. Costimulation modulation with abatacept in patients with recent-onset type 1 diabetes: follow-up 1 year after cessation of treatment. Diabetes Care. 2014 Apr; 37(4):1069-75.
    View in: PubMed
    Score: 0.033
  86. Rigby MR, DiMeglio LA, Rendell MS, Felner EI, Dostou JM, Gitelman SE, Patel CM, Griffin KJ, Tsalikian E, Gottlieb PA, Greenbaum CJ, Sherry NA, Moore WV, Monzavi R, Willi SM, Raskin P, Moran A, Russell WE, Pinckney A, Keyes-Elstein L, Howell M, Aggarwal S, Lim N, Phippard D, Nepom GT, McNamara J, Ehlers MR. Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Diabetes Endocrinol. 2013 Dec; 1(4):284-94.
    View in: PubMed
    Score: 0.033
  87. Pescovitz MD, Greenbaum CJ, Bundy B, Becker DJ, Gitelman SE, Goland R, Gottlieb PA, Marks JB, Moran A, Raskin P, Rodriguez H, Schatz DA, Wherrett DK, Wilson DM, Krischer JP, Skyler JS. B-lymphocyte depletion with rituximab and ?-cell function: two-year results. Diabetes Care. 2014 Feb; 37(2):453-9.
    View in: PubMed
    Score: 0.033
  88. Gitelman SE, Gottlieb PA, Rigby MR, Felner EI, Willi SM, Fisher LK, Moran A, Gottschalk M, Moore WV, Pinckney A, Keyes-Elstein L, Aggarwal S, Phippard D, Sayre PH, Ding L, Bluestone JA, Ehlers MR. Antithymocyte globulin treatment for patients with recent-onset type 1 diabetes: 12-month results of a randomised, placebo-controlled, phase 2 trial. Lancet Diabetes Endocrinol. 2013 Dec; 1(4):306-16.
    View in: PubMed
    Score: 0.033
  89. Herold KC, Gitelman SE, Ehlers MR, Gottlieb PA, Greenbaum CJ, Hagopian W, Boyle KD, Keyes-Elstein L, Aggarwal S, Phippard D, Sayre PH, McNamara J, Bluestone JA. Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders. Diabetes. 2013 Nov; 62(11):3766-74.
    View in: PubMed
    Score: 0.033
  90. Roep BO, Solvason N, Gottlieb PA, Abreu JRF, Harrison LC, Eisenbarth GS, Yu L, Leviten M, Hagopian WA, Buse JB, von Herrath M, Quan J, King RS, Robinson WH, Utz PJ, Garren H, Steinman L. Plasmid-encoded proinsulin preserves C-peptide while specifically reducing proinsulin-specific CD8? T cells in type 1 diabetes. Sci Transl Med. 2013 Jun 26; 5(191):191ra82.
    View in: PubMed
    Score: 0.033
  91. Lebastchi J, Deng S, Lebastchi AH, Beshar I, Gitelman S, Willi S, Gottlieb P, Akirav EM, Bluestone JA, Herold KC. Immune therapy and ?-cell death in type 1 diabetes. Diabetes. 2013 May; 62(5):1676-80.
    View in: PubMed
    Score: 0.032
  92. Herold KC, Gitelman SE, Willi SM, Gottlieb PA, Waldron-Lynch F, Devine L, Sherr J, Rosenthal SM, Adi S, Jalaludin MY, Michels AW, Dziura J, Bluestone JA. Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period: a randomised controlled trial. Diabetologia. 2013 Feb; 56(2):391-400.
    View in: PubMed
    Score: 0.031
  93. Loechelt BJ, Boulware D, Green M, Baden LR, Gottlieb P, Krause-Steinrauf H, Weinberg A. Epstein-Barr and other herpesvirus infections in patients with early onset type 1 diabetes treated with daclizumab and mycophenolate mofetil. Clin Infect Dis. 2013 Jan; 56(2):248-54.
    View in: PubMed
    Score: 0.031
  94. Alkanani AK, Rewers M, Dong F, Waugh K, Gottlieb PA, Zipris D. Dysregulated Toll-like receptor-induced interleukin-1? and interleukin-6 responses in subjects at risk for the development of type 1 diabetes. Diabetes. 2012 Oct; 61(10):2525-33.
    View in: PubMed
    Score: 0.030
  95. Greenbaum CJ, Beam CA, Boulware D, Gitelman SE, Gottlieb PA, Herold KC, Lachin JM, McGee P, Palmer JP, Pescovitz MD, Krause-Steinrauf H, Skyler JS, Sosenko JM. Fall in C-peptide during first 2 years from diagnosis: evidence of at least two distinct phases from composite Type 1 Diabetes TrialNet data. Diabetes. 2012 Aug; 61(8):2066-73.
    View in: PubMed
    Score: 0.030
  96. Lachin JM, McGee PL, Greenbaum CJ, Palmer J, Pescovitz MD, Gottlieb P, Skyler J. Sample size requirements for studies of treatment effects on beta-cell function in newly diagnosed type 1 diabetes. PLoS One. 2011; 6(11):e26471.
    View in: PubMed
    Score: 0.029
  97. Mallone R, Scotto M, Janicki CN, James EA, Fitzgerald-Miller L, Wagner R, Gottlieb P, Thorpe J, Jospe N, Durinovic-Bell? I, Boitard C, Lou O, Dayan CM, Wong FS. Immunology of Diabetes Society T-Cell Workshop: HLA class I tetramer-directed epitope validation initiative T-Cell Workshop Report-HLA Class I Tetramer Validation Initiative. Diabetes Metab Res Rev. 2011 Nov; 27(8):720-6.
    View in: PubMed
    Score: 0.029
  98. James EA, Mallone R, Schloot NC, Gagnerault MC, Thorpe J, Fitzgerald-Miller L, Reichow J, Wagner R, Pham MN, Jospe N, Lou O, Gottlieb PA, Brooks-Worrell BM, Durinovic-Bell? I. Immunology of Diabetes Society T-Cell Workshop: HLA class II tetramer-directed epitope validation initiative. Diabetes Metab Res Rev. 2011 Nov; 27(8):727-36.
    View in: PubMed
    Score: 0.029
  99. Brooks-Worrell B, Tree T, Mannering SI, Durinovic-Bello I, James E, Gottlieb P, Wong S, Zhou Z, Yang L, Cilio CM, Reichow J, Menart B, Rutter R, Schreiner R, Pham M, Petrich de Marquesini L, Lou O, Scotto M, Mallone R, Schloot NC. Comparison of cryopreservation methods on T-cell responses to islet and control antigens from type 1 diabetic patients and controls. Diabetes Metab Res Rev. 2011 Nov; 27(8):737-45.
    View in: PubMed
    Score: 0.029
  100. Michels AW, Ostrov DA, Zhang L, Nakayama M, Fuse M, McDaniel K, Roep BO, Gottlieb PA, Atkinson MA, Eisenbarth GS. Structure-based selection of small molecules to alter allele-specific MHC class II antigen presentation. J Immunol. 2011 Dec 01; 187(11):5921-30.
    View in: PubMed
    Score: 0.029
  101. Orban T, Bundy B, Becker DJ, DiMeglio LA, Gitelman SE, Goland R, Gottlieb PA, Greenbaum CJ, Marks JB, Monzavi R, Moran A, Raskin P, Rodriguez H, Russell WE, Schatz D, Wherrett D, Wilson DM, Krischer JP, Skyler JS. Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial. Lancet. 2011 Jul 30; 378(9789):412-9.
    View in: PubMed
    Score: 0.028
  102. Wherrett DK, Bundy B, Becker DJ, DiMeglio LA, Gitelman SE, Goland R, Gottlieb PA, Greenbaum CJ, Herold KC, Marks JB, Monzavi R, Moran A, Orban T, Palmer JP, Raskin P, Rodriguez H, Schatz D, Wilson DM, Krischer JP, Skyler JS. Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial. Lancet. 2011 Jul 23; 378(9788):319-27.
    View in: PubMed
    Score: 0.028
  103. Gottlieb PA, Handler ES, Appel MC, Greiner DL, Mordes JP, Rossini AA. Insulin treatment prevents diabetes mellitus but not thyroiditis in RT6-depleted diabetes resistant BB/Wor rats. Diabetologia. 1991 May; 34(5):296-300.
    View in: PubMed
    Score: 0.028
  104. Dang M, Rockell J, Wagner R, Wenzlau JM, Yu L, Hutton JC, Gottlieb PA, Davidson HW. Human type 1 diabetes is associated with T cell autoimmunity to zinc transporter 8. J Immunol. 2011 May 15; 186(10):6056-63.
    View in: PubMed
    Score: 0.028
  105. Young KA, Snell-Bergeon JK, Naik RG, Hokanson JE, Tarullo D, Gottlieb PA, Garg SK, Rewers M. Vitamin D deficiency and coronary artery calcification in subjects with type 1 diabetes. Diabetes Care. 2011 Feb; 34(2):454-8.
    View in: PubMed
    Score: 0.027
  106. Meyers AJ, Shah RR, Gottlieb PA, Zipris D. Altered Toll-like receptor signaling pathways in human type 1 diabetes. J Mol Med (Berl). 2010 Dec; 88(12):1221-31.
    View in: PubMed
    Score: 0.027
  107. Pescovitz MD, Greenbaum CJ, Krause-Steinrauf H, Becker DJ, Gitelman SE, Goland R, Gottlieb PA, Marks JB, McGee PF, Moran AM, Raskin P, Rodriguez H, Schatz DA, Wherrett D, Wilson DM, Lachin JM, Skyler JS. Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. N Engl J Med. 2009 Nov 26; 361(22):2143-52.
    View in: PubMed
    Score: 0.025
  108. Triolo TM, Baschal EE, Armstrong TK, Toews CS, Fain PR, Rewers MJ, Yu L, Miao D, Eisenbarth GS, Gottlieb PA, Barker JM. Homozygosity of the polymorphism MICA5.1 identifies extreme risk of progression to overt adrenal insufficiency among 21-hydroxylase antibody-positive patients with type 1 diabetes. J Clin Endocrinol Metab. 2009 Nov; 94(11):4517-23.
    View in: PubMed
    Score: 0.025
  109. Bradshaw EM, Raddassi K, Elyaman W, Orban T, Gottlieb PA, Kent SC, Hafler DA. Monocytes from patients with type 1 diabetes spontaneously secrete proinflammatory cytokines inducing Th17 cells. J Immunol. 2009 Oct 01; 183(7):4432-9.
    View in: PubMed
    Score: 0.025
  110. Herold KC, Brooks-Worrell B, Palmer J, Dosch HM, Peakman M, Gottlieb P, Reijonen H, Arif S, Spain LM, Thompson C, Lachin JM. Validity and reproducibility of measurement of islet autoreactivity by T-cell assays in subjects with early type 1 diabetes. Diabetes. 2009 Nov; 58(11):2588-95.
    View in: PubMed
    Score: 0.025
  111. Herold KC, Gitelman S, Greenbaum C, Puck J, Hagopian W, Gottlieb P, Sayre P, Bianchine P, Wong E, Seyfert-Margolis V, Bourcier K, Bluestone JA. Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years. Clin Immunol. 2009 Aug; 132(2):166-73.
    View in: PubMed
    Score: 0.024
  112. Gottlieb PA, Rossini AA, Mordes JP. Approaches to prevention and treatment of IDDM in animal models. Diabetes Care. 1988 Nov-Dec; 11 Suppl 1:29-36.
    View in: PubMed
    Score: 0.024
  113. Wenzlau JM, Juhl K, Yu L, Moua O, Sarkar SA, Gottlieb P, Rewers M, Eisenbarth GS, Jensen J, Davidson HW, Hutton JC. The cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in human type 1 diabetes. Proc Natl Acad Sci U S A. 2007 Oct 23; 104(43):17040-5.
    View in: PubMed
    Score: 0.022
  114. Garg SK, Kelly WC, Voelmle MK, Ritchie PJ, Gottlieb PA, McFann KK, Ellis SL. Continuous home monitoring of glucose: improved glycemic control with real-life use of continuous glucose sensors in adult subjects with type 1 diabetes. Diabetes Care. 2007 Dec; 30(12):3023-5.
    View in: PubMed
    Score: 0.022
  115. Haller MJ, Gottlieb PA, Schatz DA. Type 1 diabetes intervention trials 2007: where are we and where are we going? Curr Opin Endocrinol Diabetes Obes. 2007 Aug; 14(4):283-7.
    View in: PubMed
    Score: 0.022
  116. Waid DM, Wagner RJ, Putnam A, Vaitaitis GM, Pennock ND, Calverley DC, Gottlieb P, Wagner DH. A unique T cell subset described as CD4loCD40+ T cells (TCD40) in human type 1 diabetes. Clin Immunol. 2007 Aug; 124(2):138-48.
    View in: PubMed
    Score: 0.021
  117. Brusko T, Wasserfall C, McGrail K, Schatz R, Viener HL, Schatz D, Haller M, Rockell J, Gottlieb P, Clare-Salzler M, Atkinson M. No alterations in the frequency of FOXP3+ regulatory T-cells in type 1 diabetes. Diabetes. 2007 Mar; 56(3):604-12.
    View in: PubMed
    Score: 0.021
  118. Ouyang Q, Standifer NE, Qin H, Gottlieb P, Verchere CB, Nepom GT, Tan R, Panagiotopoulos C. Recognition of HLA class I-restricted beta-cell epitopes in type 1 diabetes. Diabetes. 2006 Nov; 55(11):3068-74.
    View in: PubMed
    Score: 0.020
  119. Barker JM, Yu J, Yu L, Wang J, Miao D, Bao F, Hoffenberg E, Nelson JC, Gottlieb PA, Rewers M, Eisenbarth GS. Autoantibody "subspecificity" in type 1 diabetes: risk for organ-specific autoimmunity clusters in distinct groups. Diabetes Care. 2005 Apr; 28(4):850-5.
    View in: PubMed
    Score: 0.018
  120. Izuora KE, Chase HP, Jackson WE, Coll JR, Osberg IM, Gottlieb PA, Rewers MJ, Garg SK. Inflammatory markers and diabetic retinopathy in type 1 diabetes. Diabetes Care. 2005 Mar; 28(3):714-5.
    View in: PubMed
    Score: 0.018
  121. Steck AK, Barriga KJ, Emery LM, Fiallo-Scharer RV, Gottlieb PA, Rewers MJ. Secondary attack rate of type 1 diabetes in Colorado families. Diabetes Care. 2005 Feb; 28(2):296-300.
    View in: PubMed
    Score: 0.018
  122. Garg SK, Gottlieb PA, Hisatomi ME, D'Souza A, Walker AJ, Izuora KE, Chase HP. Improved glycemic control without an increase in severe hypoglycemic episodes in intensively treated patients with type 1 diabetes receiving morning, evening, or split dose insulin glargine. Diabetes Res Clin Pract. 2004 Oct; 66(1):49-56.
    View in: PubMed
    Score: 0.018
  123. Ott PA, Dittrich MT, Herzog BA, Guerkov R, Gottlieb PA, Putnam AL, Durinovic-Bello I, Boehm BO, Tary-Lehmann M, Lehmann PV. T cells recognize multiple GAD65 and proinsulin epitopes in human type 1 diabetes, suggesting determinant spreading. J Clin Immunol. 2004 Jul; 24(4):327-39.
    View in: PubMed
    Score: 0.017
  124. Kelemen K, Gottlieb PA, Putnam AL, Davidson HW, Wegmann DR, Hutton JC. HLA-DQ8-associated T cell responses to the diabetes autoantigen phogrin (IA-2 beta) in human prediabetes. J Immunol. 2004 Mar 15; 172(6):3955-62.
    View in: PubMed
    Score: 0.017
  125. Garg SK, Walker AJ, Hoff HK, D'Souza AO, Gottlieb PA, Chase HP. Glycemic parameters with multiple daily injections using insulin glargine versus insulin pump. Diabetes Technol Ther. 2004 Feb; 6(1):9-15.
    View in: PubMed
    Score: 0.017
  126. Schloot NC, Meierhoff G, Karlsson Faresj? M, Ott P, Putnam A, Lehmann P, Gottlieb P, Roep BO, Peakman M, Tree T. Comparison of cytokine ELISpot assay formats for the detection of islet antigen autoreactive T cells. Report of the third immunology of diabetes society T-cell workshop. J Autoimmun. 2003 Dec; 21(4):365-76.
    View in: PubMed
    Score: 0.017
  127. Garg SK, Frias JP, Anil S, Gottlieb PA, MacKenzie T, Jackson WE. Insulin lispro therapy in pregnancies complicated by type 1 diabetes: glycemic control and maternal and fetal outcomes. Endocr Pract. 2003 May-Jun; 9(3):187-93.
    View in: PubMed
    Score: 0.016
  128. Lee PT, Putnam A, Benlagha K, Teyton L, Gottlieb PA, Bendelac A. Testing the NKT cell hypothesis of human IDDM pathogenesis. J Clin Invest. 2002 Sep; 110(6):793-800.
    View in: PubMed
    Score: 0.015
  129. Alleva DG, Gaur A, Jin L, Wegmann D, Gottlieb PA, Pahuja A, Johnson EB, Motheral T, Putnam A, Crowe PD, Ling N, Boehme SA, Conlon PJ. Immunological characterization and therapeutic activity of an altered-peptide ligand, NBI-6024, based on the immunodominant type 1 diabetes autoantigen insulin B-chain (9-23) peptide. Diabetes. 2002 Jul; 51(7):2126-34.
    View in: PubMed
    Score: 0.015
  130. Eisenbarth GS, Moriyama H, Robles DT, Liu E, Yu L, Babu S, Redondo MJ, Redondo M, Gottlieb P, Wegmann D, Rewers M. Insulin autoimmunity: prediction/precipitation/prevention type 1A diabetes. Autoimmun Rev. 2002 May; 1(3):139-45.
    View in: PubMed
    Score: 0.015
  131. Alleva DG, Crowe PD, Jin L, Kwok WW, Ling N, Gottschalk M, Conlon PJ, Gottlieb PA, Putnam AL, Gaur A. A disease-associated cellular immune response in type 1 diabetics to an immunodominant epitope of insulin. J Clin Invest. 2001 Jan; 107(2):173-80.
    View in: PubMed
    Score: 0.014
  132. Garg SK, Anderson JH, Gerard LA, Mackenzie TA, Gottlieb PA, Jennings MK, Chase HP. Impact of insulin lispro on HbA1c values in insulin pump users. Diabetes Obes Metab. 2000 Oct; 2(5):307-11.
    View in: PubMed
    Score: 0.013
  133. Redondo MJ, Gottlieb PA, Motheral T, Mulgrew C, Rewers M, Babu S, Stephens E, Wegmann DR, Eisenbarth GS. Heterophile anti-mouse immunoglobulin antibodies may interfere with cytokine measurements in patients with HLA alleles protective for type 1A diabetes. Diabetes. 1999 Nov; 48(11):2166-70.
    View in: PubMed
    Score: 0.013
  134. Roep BO, Atkinson MA, van Endert PM, Gottlieb PA, Wilson SB, Sachs JA. Autoreactive T cell responses in insulin-dependent (Type 1) diabetes mellitus. Report of the first international workshop for standardization of T cell assays. J Autoimmun. 1999 Sep; 13(2):267-82.
    View in: PubMed
    Score: 0.012
  135. Yu L, Brewer KW, Gates S, Wu A, Wang T, Babu SR, Gottlieb PA, Freed BM, Noble J, Erlich HA, Rewers MJ, Eisenbarth GS. DRB1*04 and DQ alleles: expression of 21-hydroxylase autoantibodies and risk of progression to Addison's disease. J Clin Endocrinol Metab. 1999 Jan; 84(1):328-35.
    View in: PubMed
    Score: 0.012
  136. Ostrov DA, Alkanani A, McDaniel KA, Case S, Baschal EE, Pyle L, Ellis S, P?llinger B, Seidl KJ, Shah VN, Garg SK, Atkinson MA, Gottlieb PA, Michels AW. Methyldopa blocks MHC class II binding to disease-specific antigens in autoimmune diabetes. J Clin Invest. 2018 05 01; 128(5):1888-1902.
    View in: PubMed
    Score: 0.011
  137. James EA, Abreu JRF, McGinty JW, Odegard JM, Filli? YE, Hocter CN, Culina S, Ladell K, Price DA, Alkanani A, Rihanek M, Fitzgerald-Miller L, Skowera A, Speake C, Gottlieb P, Davidson HW, Wong FS, Roep B, Mallone R. Combinatorial detection of autoreactive CD8+ T cells with HLA-A2 multimers: a multi-centre study by the Immunology of Diabetes Society T Cell Workshop. Diabetologia. 2018 03; 61(3):658-670.
    View in: PubMed
    Score: 0.011
  138. Simone E, Daniel D, Schloot N, Gottlieb P, Babu S, Kawasaki E, Wegmann D, Eisenbarth GS. T cell receptor restriction of diabetogenic autoimmune NOD T cells. Proc Natl Acad Sci U S A. 1997 Mar 18; 94(6):2518-21.
    View in: PubMed
    Score: 0.011
  139. Liu W, Putnam AL, Xu-Yu Z, Szot GL, Lee MR, Zhu S, Gottlieb PA, Kapranov P, Gingeras TR, Fazekas de St Groth B, Clayberger C, Soper DM, Ziegler SF, Bluestone JA. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J Exp Med. 2006 Jul 10; 203(7):1701-11.
    View in: PubMed
    Score: 0.005
  140. Chipkin SR, Gottlieb P, Lundstrom R, Leppo J, Aronin N. Transient myocardial perfusion abnormalities in diabetic patients: a prospective study using thallium exercise tolerance testing. Cardiology. 1991; 79(3):172-9.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)